Journal Home
Search for

Volume 36, Issue 4, Pages 340-342 (October 2010)


View previous. 9 of 23 View next.

Rapidly spreading CTX-M-type β-lactamase-producing Proteus mirabilis in Japan

Akiko Kanayamaa, Takako Iyodab, Kaoru Matsuzakib, Takeshi Saikab, Fumiaki Ikedab, Yoshikazu Ishiic, Keizo Yamaguchic, Intetsu KobayashiaCorresponding Author Informationemail address

Received 19 February 2010; accepted 2 June 2010. published online 08 July 2010.

Abstract 

In recent years, increased isolation of extended-spectrum β-lactamase (ESBL)-producing Proteus mirabilis has been reported in Japan. We undertook an investigation to determine the prevalence of ESBL-producing P. mirabilis isolated in Japan and to characterise the genotype. Seventy-four P. mirabilis isolates recovered from specimens at 54 hospitals in Japan between March and October 2006 were included in the study. Of the 74 P. mirabilis isolates examined, 28 (37.8%) were ESBL-producers. The blaCTX-M-2 gene was found in 27 isolates, whilst 1 isolate possessed blaCTX-M-3. Amongst the 28 ESBL-producers, 25 (89.3%) were non-susceptible to ciprofloxacin, whilst 11 (23.9%) of 46 ESBL-non-producing isolates were non-susceptible to ciprofloxacin. Pulsed-field gel electrophoresis (PFGE) analysis of the 28 ESBL-producing isolates from 19 hospitals revealed 17 clusters. The same PFGE type was observed in two or more hospitals especially in the greater Tokyo area, suggesting possible clonal spread and the need for monitoring to determine whether emergence of a dominant clone occurs. Our results show that in Japan there is a high prevalence of CTX-M-type β-lactamase-producing P. mirabilis. Moreover, these isolates are characterised by reduced susceptibility to fluoroquinolones.

a Department of Infection Control and Prevention, Faculty of Medicine, Toho University, 4-16-20, Omori-nishi, Ota-ku, Tokyo 143-0015, Japan

b Chemotherapy Division, Mitsubishi Chemical Medience Corporation, 3-30-1, Shimura, Itabashi-ku, Tokyo 174-8555, Japan

c Department of Microbiology and Infectious Diseases, School of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, Tokyo 143-8540, Japan

Corresponding Author InformationCorresponding author. Tel.: +81 3 3762 9247; fax: +81 3 3762 9247.

PII: S0924-8579(10)00239-6

doi:10.1016/j.ijantimicag.2010.06.002


View previous. 9 of 23 View next.